

THE GUT-LIVER AXIS

07 - 09 JUNE 2018

LEUVEN, BELGIUM

SCIENTIFIC ORGANISING COMMITTEE

Agustin Albillos, *Spain*
Andrea De Gottardi, *Switzerland*
Maria Rescigno, *Italy*

PRELIMINARY* PROGRAMME

Thursday 07 June 2018

- 13:45 – 14:00 **Welcome message**
Agustin Albillos, *Spain*
Andrea de Gottardi, *Switzerland*
Maria Rescigno, *Italy*
- 14:00 – 14:15 **Opening Remarks**
Jeroen Raes, *Belgium*
- 14:15 – 15:00 **State-of-the-art lecture**
The basis of the gut liver axis
Speaker to be confirmed

Session I: From single components to integrated signaling

Chairs: Maria Rescigno, *Italy*
Andrew Macpherson, *Switzerland*

- 15:00 - 15:25 **Structure and function of the intestinal barrier**
Maria Rescigno, *Italy*
- 15:25 – 15:50 **Enteroendocrine and cytokine signaling**
Speaker to be confirmed
- 15:50 – 16:15 **Circulation and homing of immune cells**
David Adams, *United Kingdom*
- 16:15 – 16:40 **Bile acid signaling in the gut-liver axis**
Speaker to be confirmed
- 16:40 – 17:10 *ePoster session and coffee break*

*Subject to change

Session 2: The impact of intestinal alterations for the pathophysiology of liver diseases

Chairs: Tom Karlsen, *Norway*
Jeroen Raes, *Belgium*

17:10 – 17:35

Disturbances of gut microbiota on liver inflammation and fibrosis

Bernd Schnabl, *United States*

17:35 – 18:00

Contribution of intestinal inflammation and dysbiosis to cholestatic liver disease

Johannes Hov, *Norway*

18:00 – 18:25

The gut-liver axis in the control of hepatobiliary malignancies

Antonio Moschetta, *Italy*

18:25 – 18:50

Liver and gut-derived inflammation in the pathophysiology of ACLF

Jonel Trebicka, *Germany*

18:50 – 19:10

Industry point of view: Targeting the intestine in gut-liver axis

Speaker to be confirmed

19:10 – 20:10

ePoster session and cocktail reception

*Subject to change

Friday 08 June 2018

Session 3: Lifestyle and exposure contributions to intestinal homeostasis

Chairs: Andrea de Gottardi, *Switzerland*
Thierry Gustot, *Belgium*

- 08:30 – 08:55 **Effects of xenobiotics and nutrition on the ecology of intestinal microbiota**
Jeroen Raes, *Belgium*
- 08:55 – 09:20 **Health care exposure and multidrug resistant bacteria infections in cirrhosis**
Pere Ginés, *Spain*
- 09:20 – 09:45 **The intestinal mucus and environmental exposures**
Malin Johansson, *Sweden*
- 09:45 – 10:05 **Industry point of view: Antibiotics to modulate the gut-liver-axis**
Speaker to be confirmed
- 10:05 – 11:00 **Abstract session**
- 11:00 – 11:30 *ePoster Session and Coffee Break*

Session 4: The impact of liver disease on the gut-liver axis

Chairs: Agustin Albillos, *Spain*
Rajiv Jalan, *United Kingdom*

- 11:30 – 11:55 **Effects of NAFLD on the gut microbiota and lipid metabolism**
Patrice Cani, *Belgium*
- 11:55 – 12:20 **Interaction between intestine and liver in alcoholic liver disease**
Ramón Bataller, *United States*
- 12:20 – 12:45 **Intestinal barrier failure in cirrhosis: impact on complications**
Agustin Albillos, *Spain*
- 12:45 – 13:05 **Industry point of view: FXR agonists or antagonists**
Speaker to be confirmed
- 13:10 – 14:15 *ePoster session and Lunch break*

*Subject to change

Session 5: Debate session: the optimal “toolbox” to address the gut-liver axis

Chairs: Bernd Schnabl, *United States*
Kathy McCoy, *Canada*

14:30 – 14:50

Gnotobiotic animal models

Kathy McCoy, *Canada*

14:50 – 15:10

Assessment of intestinal permeability and translocation

Ingvar Bjarnason, *United Kingdom*

15:10 – 15:30

Endoscopy and imaging tools

Reiner Wiest, *Switzerland*

15:30 – 15:50

Industry point of view: Diagnostic technology company

Speaker to be confirmed

15:50 – 16:30

ePoster Session and coffee break

16:30 – 17:15

State-of-the-art lecture

Host control of the gut microbiota: The case of liver disease

Andrew Macpherson, *Switzerland*

Session 6: Intervention - gut - centric aspects

Chairs: David Adams, *United Kingdom*

17:15 – 17:40

Personalized nutrition

Eran Segal Segal, *Israel*

17:40 – 18:05

Next generation probiotics

Speaker to be confirmed

18:05 – 18:30

Fecal transplantation in cirrhosis

Jasmohan Bajaj, *United States*

18:30 – 18:55

Impact of gut microbiome in therapy: lessons from oncology

Laurence Zitvogel, *France*

18:55 – 19:20

Nanoporous carbon adsorbent to modify liver disease

Rajiv Jalan, *United Kingdom*

19:20 – 19:35

Industry point of view: Impact of ingested bacteria on human gut microbiota

Muriel Derrien, *France*

*Subject to change

Saturday 09 June 2018

Session 7: Intervention – liver-centric aspects

Chairs: Massimo Pinzani, *United Kingdom*
Frederik Nevens, *Belgium*

09:00 – 09:25

Bile acid signaling and the FXR pathway

Michael Trauner, *Austria*

09:25 – 09:50

Modulating the gut-liver axis in cirrhosis and portal hypertension

Andrea De Gottardi, *Switzerland*

09:50 – 10:15

The inflammasome as a target of the gut-liver axis

Speaker to be confirmed

10:15 – 10:35

Industry point of view: Probiotics in liver disease

Speaker to be confirmed

10:35 – 10:55

Industry point of view: FXR agonists and beyond

Speaker to be confirmed

10:55 – 11:30

ePoster session and coffee break

Session 8: Debate: The future of the gut-liver axis in hepatology

Chairs: Agustin Albillos, *Spain*
Andrea De Gottardi, *Switzerland*
Maria Rescigno, *Italy*

11:30 – 11:50

Unmet technical and methodological needs

Speaker to be confirmed

11:50 – 12:10

10 Drug and xenobiotic metabolism and the gut microbiota

Jeremy Nicholson, *United Kingdom*

12:10 – 12:30

Designing clinical trials targeting the gut microbiota

Max Niewdorp, *The Netherlands*

12:30 – 12:45

Closing remarks

Agustin Albillos, *Spain*
Andrea De Gottardi, *Switzerland*
Maria Rescigno, *Italy*

*Subject to change